Mr Jeff Davidson
Keystone Nano (KN) is a developing two nanotechnology platforms to solve problems in the treatment of cancer. Both the Ceramide NanoLiposome (CNL) and the NanoJacket (NJ) precisely deliver therapies to tumors and address a $50 billion cancer therapeutic market where single products routinely exceed a billion in sales. KN’s technology was licensed from Penn State, and is distinct from all technology in development and has substantial technological advantages. KN technology is an advanced stage of development is supported by considerable intellectual property and a successful multi-disciplinary commercialization team.
KN also creates custom nanoparticles for client companies designed to allow the creation of new products of value with highly unique features. KN has worked with a wide range of pharmaceutical clients in this manner, and can do so in a milestone based manner.
Keystone Nano, Inc.
CEO
Ms Lisa Decker
Nektar Therapeutics is a clinical-stage biopharmaceutical company developing a pipeline of drug candidates that utilize its PEGylation and polymer conjugate technology platforms, which are designed to improve the benefits of drugs for patients. Its product pipeline consists of drug candidates across a number of therapeutic areas, including oncology, pain, anti-infectives, anti-viral and immunology. Nektar's research and development activities involve small molecule drugs, peptides and other potential biologic drug candidates. Its drug candidates are designed to improve the pharmacokinetics, pharmacodynamics, half-life, bioavailability, metabolism or distribution of drugs and improve the overall benefits and use of a drug for the patient.
Nektar is well-respected as a partner-of-choice with the world's leading pharmaceutical and biotechnology companies. Our platform technologies are validated and used in many of today's top-selling commercial drugs. As a result, industry returns to us time and time again to co-develop the next-generation of successful drugs designed to meet critical unmet medical needs.
Our strategic partnerships range from joint discovery and co-development to licensing and royalty arrangements with a wide range of organizations.
Nektar Therapeutics
Executive Director, Business DevelopmentAmy Diebler
Cornerstone Therapeutics Inc. is a specialty pharmaceutical company focused on commercializing products for the hospital, niche respiratory and related specialty markets. Key elements of the Company’s strategy are to focus its commercial and development efforts in the hospital and related specialty product sector within the U.S. pharmaceutical marketplace; continue to seek out opportunities to acquire companies and marketed and/or registration-stage products that fit within the Company’s focus areas; and generate revenues by marketing approved generic products through the Company’s wholly owned subsidiary, Aristos Pharmaceuticals, Inc.
Cornerstone Therapeutics
Senior Director, Corporate Finance and Development
Miss Heather Dragon
EvaluatePharma®, leader in life science sector analysis, delivers exclusive commercial intelligence and analysis into industry performance globally.
With 10+ years’ experience and investment in our services, we provide meaningful, value-added information and analysis that aids in target identification, strategic decision-making, and risk mitigation aimed towards your competitive advantage and business results.
Our flexible, “one-stop” services include:
EvaluatePharma® featuring all the Deals Data you need for Business Development, Proprietary Data Standardization, Merge Company tool, Calendar of Events, Interactive NPV Analyzer, Sales by Indication and Consensus Forecasts for Marketed & Pipeline Products, plus much more to give you the most accurate view of the global market.
EP Clinical Trials simplifies complex analysis of the global clinical trials landscape including ClinicalTrials.gov, EudraCT and Japan clinical trials data source for trusted clinical intelligence you can rely on, and the time savings you need.
EvaluatePharma® Partnering Services make finding your next licensing partner easier, and features the latest assets available for partnering presented in their commercial context alongside our unique industry analysis.
EPVantage® renowned news service provides mapped commentary and analysis that keeps you abreast of the latest sector developments relevant to you.
Discover why EvaluatePharma is trusted and relied upon by life science companies big and small, the investment community and leading consultancies.
You can count on EvaluatePharma for:
• Product Forecasts to 2018
• New – Sales by Indication to 2018
• Product Deals
• M&A Transactions
• Product Historic Sales
• Clinical Trials
• Country Analysis
• Archived Historical Sales Forecasts
• Company profiles
• Drug Information
• R&D Pipelines
• Patent Risk
• News
• NPV’s of Marketed and Pipeline Products
• Calendar of Events - key events that will shape the future of the industry
• EP Vantage & Event Analyzer - analysis and commentary on key market events
| Partnering strategy/collaborations |
| We encourage all biotechnology companies and research organizations with developmental products available to out-license to post their licensing details to our Partnering Opportunities service. This new free service allows potential partners to see your Partnering Opportunities in their commercial context, alongside EvaluatePharma®’s unique industry analysis, including product portfolios, company financials and reference deal terms. |
| Client portfolio |
|
EvaluatePharma® has a global audience of business development and licensing professionals at the world's leading pharmaceuticals and biopharmaceuticals companies - we have Users at 85 of the top 100 pharma companies, worldwide, with more signing up every day. We look forward to meeting you at the conference! |
EvaluatePharma USA, Inc.
Manager, Sales & Solutions
Mr Luke Duster
Capital Royalty, L.P.
Principal
Dr Gabriel Eichler, Ph.D.
Relay brings you BD Live! – a software solution providing business intelligence to life science professionals to validate opportunities, discover new assets, and assess their pipelines against their competitors. BD Live! provides real-time trend monitoring and comparative asset analysis and complements existing evaluation models to help business development professionals hone in on promising new technologies and avoid transactions that have limited potential.
Relay Technology Management
SVP Consulting Services
Mr Craig Farrell
GLG Research partners with organizations seeking efficient, targeted connections to insight.
Our Healthcare Practice provides you with access to expert insights on issues affecting the pharmaceutical, biotechnology, medical device, and healthcare services sectors. GLG works with:
- 9 of the top 10 pharmaceutical and biotechnology companies
- More than 80,000 experts from across the entire healthcare industry including physicians, researchers, scientists, payors, and healthcare industry executives
- 7 out of the top 10 global medical equipment companies
- Over 300,000 experts from all sectors, including former C-level operating executives, ex-top-tier strategy consultants and thought leaders from around the world
Gerson Lehrman Group
Vice President, Business Development
Mr Robert Finizio
TherapeuticsMD (TXMD) is a publicly traded Women’s Health company located in South Florida.
TXMD currently has a national sales force calling on OB-GYNs in the US and a strong pipeline of late stage HRT products. We are currently pursuing in-licensing opportunities within the Women’s Health space and considering out-licensing International partners for our 3 late stage HRT products.
